Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac^® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study.

ABSTRACT:

Background

Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine regimens.

Methods

This prospective observational study assessed the immunogenicity and safety of homologous CoronaVac^® (SV-SV), ChAdOx1 nCoV-19 (AZD1222) (AZ-AZ), and the heterologous prime-boost of SV-AZ, among MHD patients.

Results

A total of 130 MHD participants were recruited. On day 28, after the second dose, seroconversion results of the surrogate virus neutralization test were not different between vaccine regimens. The magnitude of the receptor-binding do

SUBMITTER: Narongkiatikhun P 

PROVIDER: S-EPMC10146055 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature